Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson disease.
The intention of this analysis was to identify patients with treated Wilson disease (WD) and residual neurological symptoms in order to determine whether or not they were undergoing any treatment in addition to the common decoppering medication. Moreover, the effects of any symptomatic medication were analyzed. Two samples of WD patients were investigated either by a mailed questionnaire survey (n = 135) or by a retrospective analysis (n = 75). A considerable proportion of patients still suffered from neurological symptoms (n = 106, 50.5%), of whom a relatively small proportion was treated symptomatically (n = 33, 31.1%). The documented effects varied substantially, with anticholinergics and botulinum toxin (against dystonia) and primidone (against tremor) apparently being the most promising compounds. Further studies are required to analyze the symptomatic treatment of WD patients with residual neurological symptoms in more detail.
Hölscher
Sara
S
Department of Neurology, Philipps University, Marburg, Germany.
Leinweber
Barbara
B
Hefter
Harald
H
Reuner
Ulrike
U
Günther
Peter
P
Weiss
Karl Heinz
KH
Oertel
Wolfgang H
WH
Möller
Jens Carsten
JC
D000328:Adult; D000368:Aged; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D005260:Female; D006306:Health Surveys; D006527:Hepatolenticular Degeneration / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology*; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D055815:Young Adult
D018726:Anti-Dyskinesia Agents; D018680:Cholinergic Antagonists; D001905:Botulinum Toxins